The primary role of the Mouse Genetics Core is to facilitate the use of mouse molecular genetics at MSK for in vivo studies of gene functions germane to cancer. Relevant fields in which MSK investigators develop and apply mouse models include: cell growth and behavior, stem cell biology, embryonic development, immunobiology, genome integrity, cancer biology, and experimental therapeutics. The MGC consists of 2 sections: the Transgenic/Embryology Group (TgG) and the Molecular Biology/Tissue Culture Group (MBTCG). Major services offered by the TgG include the production of genetically engineered mice (GEM) by pronuclear injection of DNA or CRISPR/Cas9 and by blastocyst injection of ES cells; cryopreservation and the long-term storage of GEM lines; strain rederivation or recovery through IVF and/or embryo transfer; performance of special embryological and animal surgical procedures; and the provision of GEM lines such as CRE and FLPe expressing strains. The specialized molecular biology services provided by the MBTCG include transgene DNA purification and genotyping of founder mice; the design and production of CRISPR/Cas9 reagents for mouse genome editing; and the identification and verification of alleles carried by gene edited mice. Services offered by the MBTCG also include performing all aspects of gene targeting in mouse ES cells and establishing ES cells from GEM lines. An integral role of the MGC is to provide consultation and training in the design and production of mouse models, ES cell culture, and mouse husbandry and genetics. Rapid advances in genome editing and sequencing technologies, in combination with the steady increase in translational research at MSK, have resulted in a significant upsurge in demand for MGC services. In addition, the Core continues to pursue and implement new technical developments that will expedite gene editing in mice; ongoing efforts include the use of commercially available synthetic gRNA components and the application of electroporation to deliver CRIPSR/Cas9 into mouse zygotes. Integrating such advancements into the Core?s services will undoubtedly increase the productivity and reduce staff time/effort to create GEM models for MSK investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084827
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Lee, Stanley Chun-Wei; North, Khrystyna; Kim, Eunhee et al. (2018) Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell 34:225-241.e8
Motzer, Robert J; Escudier, Bernard; Powles, Thomas et al. (2018) Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 118:1176-1178
Giancipoli, Romina Grazia; Monti, Serena; Basturk, Olca et al. (2018) Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report. Medicine (Baltimore) 97:e12795
Karimov, Rashad R; Tan, Derek S; Gin, David Y (2018) Synthesis of the hexacyclic triterpene core of the jujuboside saponins via tandem Wolff rearrangement-intramolecular ketene hetero-Diels-Alder reaction. Tetrahedron 74:3370-3383
Fass, Josh; Sivak, David A; Crooks, Gavin E et al. (2018) Quantifying Configuration-Sampling Error in Langevin Simulations of Complex Molecular Systems. Entropy (Basel) 20:
Mauguen, Audrey; Seshan, Venkatraman E; Ostrovnaya, Irina et al. (2018) Estimating the probability of clonal relatedness of pairs of tumors in cancer patients. Biometrics 74:321-330
Tanner, Edward J; Filippova, Olga T; Gardner, Ginger J et al. (2018) A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol 151:433-437
Arbour, Kathryn C; Kris, Mark G; Riely, Gregory J et al. (2018) Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 124:105-109
Soslow, Robert A; Murali, Rajmohan (2018) A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract. Semin Diagn Pathol 35:95-107
Kao, Yu-Chien; Owosho, Adepitan A; Sung, Yun-Shao et al. (2018) BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 42:604-615

Showing the most recent 10 out of 8799 publications